Data Insights

Risk adjusted net present value: What is the current valuation of BioAtla's Ozuriftamab vedotin?

Ozuriftamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Oropharyngeal Cancer. According...

Net Present Value Model: BioAtla Inc's Ozuriftamab vedotin

Data Insights

Risk adjusted net present value: What is the current valuation of BioAtla's Ozuriftamab vedotin?

Ozuriftamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Oropharyngeal Cancer. According...

Net Present Value Model: BioAtla Inc's Ozuriftamab vedotin

Data Insights

Ozuriftamab vedotin by BioAtla for Oropharyngeal Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Oropharyngeal Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Hypopharyngeal Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Hypopharyngeal Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Laryngeal Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Laryngeal Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Oral Cavity (Mouth) Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Recurrent Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Ozuriftamab vedotin by BioAtla for Colorectal Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Colorectal Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Head And Neck Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Head And Neck Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Head And Neck Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Pancreatic Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Pancreatic Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Gastrointestinal Stromal Tumor (GIST): Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Gastrointestinal Stromal Tumor (GIST)

Data Insights

Ozuriftamab vedotin by BioAtla for Metastatic Melanoma: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Metastatic Melanoma

Data Insights

Ozuriftamab vedotin by BioAtla for Fallopian Tube Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Fallopian Tube Cancer

Data Insights

Ozuriftamab vedotin by BioAtla for Soft Tissue Sarcoma: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Soft Tissue Sarcoma

Data Insights

Ozuriftamab vedotin by BioAtla for Peritoneal Cancer: Likelihood of Approval

Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Peritoneal Cancer